Femasys Inc. Common Stock (FEMY) Stock Price

FEMYStock

$3.20−55.12%52W

Market Cap$26.80M

P/E—

PEG Ratio—

Div yield—

Beta-2.30

FEMY Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-82.57%

Price vs S&P 500 (4W)6.20%

VGM Score59.04

Book Value / Share (Quarterly)$2.41

P/TBV (Annual)5.98x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)23.75%

Cash Flow / Share (Quarterly)$-6.19

Price vs S&P 500 (YTD)-85.04%

Gross Margin (TTM)61.56%

Net Profit Margin (TTM)-500.01%

EPS (TTM)$-3.24

10-Day Avg Trading Volume4.00M

EPS Excl Extra (TTM)$-3.24

Revenue Growth (5Y)17.13%

EPS (Annual)$-9.42

ROI (Annual)-205.87%

Gross Margin (Annual)61.96%

Net Profit Margin (5Y Avg)-975.33%

Cash / Share (Quarterly)$1.78

Revenue Growth QoQ (YoY)24.51%

ROA (Last FY)-89.88%

Revenue Growth TTM (YoY)39.88%

EBITD / Share (TTM)$-1.69

ROE (5Y Avg)-262.99%

Operating Margin (TTM)-687.93%

Cash Flow / Share (Annual)$-6.48

P/B Ratio0.95x

P/B Ratio (Quarterly)3.48x

Net Income / Employee (Annual)$-365,300

EV / Revenue (TTM)2.05x

Net Interest Coverage (TTM)-9.41x

ROA (TTM)-70.65%

EPS Incl Extra (Annual)$-9.42

Current Ratio (Annual)4.53x

Quick Ratio (Quarterly)1.98x

3-Month Avg Trading Volume0.53M

52-Week Price Return-55.12%

Revenue / Employee (TTM)$46,600

Tangible BV / Share (Quarterly)$2.37

P/S Ratio (Annual)3.02x

Asset Turnover (Annual)0.11x

52-Week High$22.20

Operating Margin (5Y Avg)-975.52%

EPS Excl Extra (Annual)$-9.42

CapEx CAGR (5Y)83.85%

26-Week Price Return-70.64%

Quick Ratio (Annual)2.95x

13-Week Price Return-57.84%

Total Debt / Equity (Annual)0.54x

Current Ratio (Quarterly)3.91x

Enterprise Value$4.86M

Revenue / Share Growth (5Y)67.33%

Asset Turnover (TTM)0.14x

Revenue / Employee (Annual)$45,000

Inventory Turnover (Annual)0.20x

Pretax Margin (Annual)-812.21%

Cash / Share (Annual)$3.11

3-Month Return Std Dev118.82%

Gross Margin (5Y Avg)64.90%

Net Income / Employee (TTM)$-233,000

ROE (Last FY)-317.38%

Net Interest Coverage (Annual)-7.05x

EPS Basic Excl Extra (Annual)$-9.42

Receivables Turnover (TTM)11.71x

Total Debt / Equity (Quarterly)0.46x

EPS Incl Extra (TTM)$-3.24

Receivables Turnover (Annual)4.15x

ROI (TTM)-123.16%

P/S Ratio (TTM)2.91x

Pretax Margin (5Y Avg)-974.95%

Revenue / Share (Annual)$1.16

Tangible BV / Share (Annual)$1.92

Price vs S&P 500 (52W)-73.68%

Year-to-Date Return-72.22%

5-Day Price Return7.38%

EPS Normalized (Annual)$-9.42

ROA (5Y Avg)-77.24%

Net Profit Margin (Annual)-812.27%

Month-to-Date Return11.89%

Cash Flow / Share (TTM)$-0.94

EBITD / Share (Annual)$-8.72

Operating Margin (Annual)-766.96%

LT Debt / Equity (Annual)0.54x

ROI (5Y Avg)-122.54%

LT Debt / Equity (Quarterly)0.46x

EPS Basic Excl Extra (TTM)$-3.24

P/TBV (Quarterly)3.54x

P/B Ratio (Annual)5.84x

Inventory Turnover (TTM)0.18x

Pretax Margin (TTM)-499.78%

Book Value / Share (Annual)$1.97

Price vs S&P 500 (13W)-59.79%

Beta-2.30x

Revenue / Share (TTM)$0.61

ROE (TTM)-247.31%

52-Week Low$2.02

vGradeB

gGradeB

mGradeD

vgmGradeC

FEMY Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 14, 2026	-$1.40	-$1.10	+21.17%(+$0.30)
Q1 2026	May 8, 2026	-$1.80	-$1.46	+18.89%(+$0.34)
Q4 2025	Mar 31, 2026	-$1.80	-$0.20	+88.89%(+$1.60)
Q3 2025	Nov 14, 2025	-$2.60	-$2.00	+23.08%(+$0.60)
Q2 2025	Aug 8, 2025	-$3.60	-$3.20	+11.11%(+$0.40)

FEMY Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.10

4.11

Industry Peers — Surgical & Medical Instruments(140)

Symbol	Value Score	Growth Score	Momentum Score	Price
FEMYFemasys Inc. Common Stock	B	B	D	$3.20
SYKStryker Corporation	C	B	C	$330.69
MMM3M Company	C	D	C	$174.34
BSXBoston Scientific Corp.	C	B	D	$46.84
BDXBecton, Dickinson and Co.	B	D	B	$189.52
MDLNMedline Inc. Class A common stock	C	D	C	$35.28
RMDResMed Inc.	C	B	B	$240.33
DXCMDexCom, Inc.	D	B	B	$90.82
WSTWest Pharmaceutical Services, Inc.	D	C	B	$337.47
SOLVSolventum Corporation	C	C	B	$91.12
BAXBaxter International Inc.	B	D	B	$26.13
PENPenumbra, Inc.	D	C	C	$321.68
GMEDGLOBUS MEDICAL INC	B	B	C	$82.97
GKOSGlaukos Corporation	F	A	A	$179.87
PODDInsulet Corporation	C	A	C	$145.13
TFXTeleflex Incorporated	B	F	B	$139.67
STVNStevanato Group S.p.A.	D	C	C	$21.03
MMEDMiniMed Group, Inc. Common Stock	—	—	A	$20.10
MMSIMerit Medical Systems Inc	C	B	B	$90.49
HAEHaemonetics Corporation	C	C	A	$103.96
ICUIICU Medical Inc	C	D	B	$175.10
HTFLHeartflow, Inc. Common Stock	—	A	B	$47.78
IRTCiRhythm Holdings, Inc. Common Stock	F	A	C	$120.25
PLSEPulse Biosciences, Inc Common Stock (DE)	F	—	A	$47.57
ATRCAtriCure, Inc.	D	B	B	$48.54
UFPTUFP Technologies Inc	C	B	B	$300.05
NVCRNovoCure Limited Ordinary Shares	D	C	B	$17.82
LMATLeMaitre Vascular, Inc.	C	B	C	$80.45
INSPInspire Medical Systems, Inc.	B	B	B	$61.44
KMTSKestra Medical Technologies, Ltd. Common Stock	F	A	B	$25.64
TNDMTandem Diabetes Care, Inc.	D	C	B	$21.43
ATECAlphatec Holdings, Inc.	D	B	C	$9.44
DRTSAlpha Tau Medical Ltd. Ordinary Shares	—	—	A	$14.64
IARTIntegra LifeSciences Holdings	B	D	B	$16.89
AORTArtivion, Inc.	C	C	C	$26.77
PRCTPROCEPT BioRobotics Corporation Common Stock	C	A	D	$20.83
IRMDiRadimed Corporation	D	B	C	$87.07
BVSBioventus Inc. Class A Common Stock	B	C	A	$13.84
BBNXBeta Bionics, Inc. Common Stock	D	A	B	$19.72
SGPSpyGlass Pharma, Inc. Common Stock	—	—	B	$26.42
SIBNSI-BONE, Inc. Common Stock	D	B	B	$19.21
SSIISS Innovations International Inc. Common Stock	F	A	D	$3.48
MDXGMiMedx Group, Inc	C	D	C	$4.50
ANGOAngioDynamics, Inc.	C	D	A	$15.85
KIDSOrthoPediatrics Corp. Common Stock	C	B	B	$23.65
BWAYBrainsway Ltd. American Depositary Shares	F	A	B	$14.30
DCTHDelcath Systems Inc	D	B	A	$16.34
CERSCerus Corp	D	C	B	$2.65
TCMDTactile Systems Technology, Inc.	B	B	C	$23.16
NPCENeuropace, Inc. Common Stock	D	C	B	$14.41
CLPTClearPoint Neuro, Inc. Common Stock	F	A	B	$15.55

About Femasys Inc. Common Stock

Femasys develops minimally invasive medical devices for women's healthcare, offering office-based solutions for infertility treatment, contraception, and diagnostic procedures. Its product portfolio includes FemaSeed for intratubal insemination, FemVue for fallopian tube assessment, FemBloc for permanent contraception (in development), FemCerv for cervical cancer diagnosis, and FemCath and FemChec. The company generates revenue primarily from the United States market with additional international sales.